Thiamine

Thiamine operates through its active coenzyme form thiamine pyrophosphate (TPP, also called thiamine diphosphate or TDP), which is the essential cofactor for five major enzymatic activities, each critically positioned at a central node of intermediary metabolism. The TPP molecule contains a thiazolium ring whose C2 carbon is acidic and, upon deprotonation, generates a carbanion ("ylide") that executes the electrophilic addition to α-keto acid substrates that launches the reaction mechanism — a chemistry that is essentially unique to TPP among biological cofactors.

The five TPP-dependent enzymes. (1) Pyruvate dehydrogenase complex (PDH) converts pyruvate to acetyl-CoA, linking cytoplasmic glycolysis to mitochondrial TCA cycle metabolism. PDH is a massive multi-subunit complex (E1 pyruvate dehydrogenase, E2 dihydrolipoyl transacetylase, E3 dihydrolipoyl dehydrogenase), and the E1 subunit requires TPP for the initial decarboxylation of pyruvate. PDH activity is additionally regulated by PDK (pyruvate dehydrogenase kinase) phosphorylation and requires five total cofactors (TPP, lipoic acid, CoA, FAD, NAD+) — see the Alpha-Lipoic Acid entry for the parallel lipoic cofactor discussion. (2) α-Ketoglutarate dehydrogenase complex (αKGDH) is structurally homologous to PDH and catalyzes the conversion of α-ketoglutarate to succinyl-CoA in the TCA cycle, also requiring TPP at the E1 subunit. (3) Branched-chain α-keto acid dehydrogenase (BCKDH) is the third member of this enzyme family, catalyzing the oxidative decarboxylation of the α-keto acid products of branched-chain amino acid (leucine, isoleucine, valine) deamination — the step whose genetic deficiency produces maple syrup urine disease. (4) Transketolase is the TPP-dependent pentose phosphate pathway enzyme that exchanges two-carbon units between ketose and aldose sugars, producing ribose-5-phosphate for nucleotide synthesis and linking carbohydrate metabolism to NADPH generation via coordination with the oxidative arm of the pentose phosphate pathway. Erythrocyte transketolase activity with and without added TPP has historically been a key laboratory test of thiamine status. (5) 2-Hydroxyacyl-CoA lyase (HACL1) is a peroxisomal TPP-dependent enzyme involved in α-oxidation of 3-methyl-branched fatty acids (phytanic acid metabolism); this is quantitatively minor but explains some edge-case symptoms in severe deficiency.

The metabolic consequences of TPP insufficiency. Because PDH, αKGDH, and transketolase are TPP-dependent at points critical for glucose disposal and energy production, thiamine deficiency produces a predictable metabolic phenotype: (a) inability to oxidize pyruvate efficiently, causing lactate accumulation and a metabolic shift toward anaerobic glycolysis even in the presence of adequate oxygen (the "hidden lactic acidosis" of severe deficiency); (b) TCA cycle impairment at the α-ketoglutarate step; (c) impaired pentose phosphate pathway flux with reduced NADPH and ribose availability; and (d) impaired branched-chain amino acid catabolism. Brain tissue, with its near-exclusive dependence on glucose oxidation and high mitochondrial density in neurons, is exquisitely vulnerable to this combined metabolic hit. Cardiac tissue, similarly glucose- and oxidative-phosphorylation-dependent, is the second organ to fail.

Why the Wernicke-Korsakoff anatomy is stereotyped. The periaqueductal gray matter, mammillary bodies, thalamus, hypothalamus, and cerebellar vermis show characteristic necrotic and hemorrhagic lesions in acute Wernicke's, producing the clinical triad of ophthalmoplegia (especially lateral rectus palsy and nystagmus from oculomotor and abducens nuclear involvement), ataxia (cerebellar vermis and vestibular nuclei), and global confusion. The stereotyped anatomy reflects regional vulnerability in structures with exceptionally high metabolic rate and blood-brain barrier anatomy that makes them first to fail under thiamine scarcity. Persistent memory dysfunction from mammillary body and dorsomedial thalamic damage produces the Korsakoff amnestic syndrome with anterograde amnesia, retrograde amnesia, and confabulation that often persists even after acute Wernicke's is treated.

Thiamine transport and metabolism. Dietary thiamine exists in free and phosphorylated forms (primarily TPP in animal tissues). Thiamine from diet is dephosphorylated by intestinal alkaline phosphatases and transported into enterocytes predominantly by the thiamine transporter THTR2 (SLC19A3) at physiologic intakes, with passive diffusion contributing at supraphysiologic oral doses. This saturable absorption pathway has a practical implication: the maximum absorbed thiamine from a single oral dose is approximately 5-10 mg regardless of how much larger the pill; dividing higher daily doses into multiple smaller administrations captures more vitamin than a single large dose. Absorbed thiamine is phosphorylated by hepatic thiamine pyrophosphokinase (TPK1) to TPP, which is the dominant circulating and tissue form. THTR1 (SLC19A2) is the major transporter for cellular uptake of thiamine at peripheral tissues including the hematopoietic, pancreatic β-cell, and cochlear sites that fail in TRMA syndrome. A mitochondrial thiamine pyrophosphate carrier (SLC25A19) moves TPP into the mitochondrial matrix where PDH, αKGDH, and BCKDH reside. Thiamine has no substantial body store — the whole-body pool is only 25-30 mg and turnover is rapid, with biological half-life estimates ranging from 10-20 days depending on the compartment measured. This lack of reserve explains why thiamine deficiency can manifest within weeks of inadequate intake, a feature distinguishing it from fat-soluble vitamins or B12 (which can take years to deplete).

The lipophilic thiamine derivatives. The water-soluble nature of thiamine means it competes with passive diffusion efficiency across lipid membranes. Pharmaceutical development has produced several lipophilic thiamine derivatives with modified pharmacokinetics: benfotiamine (S-benzoylthiamine-O-monophosphate) is an open-ring S-acyl thiamine derivative that is absorbed via passive diffusion (bypassing THTR2 saturation), dephosphorylated by intestinal alkaline phosphatase, reduced intracellularly to yield thiamine, and produces higher tissue thiamine levels than equimolar thiamine HCl — with particular advantages for peripheral tissues studied in diabetic neuropathy. Sulbutiamine is a lipophilic disulfide dimer with isobutyryl esters that crosses the blood-brain barrier readily and has been developed as a nootropic/anti-asthenic in France; see the Sulbutiamine entry for details. Allithiamine is an S-allyl derivative found naturally in garlic and onions (and a similar mechanism — lipophilic, passively absorbed, reduced to thiamine). Fursultiamine (thiamine tetrahydrofurfuryl disulfide, sold as Alinamin in Japan) is another lipid-soluble form with similar pharmacokinetic advantages. TTFD (thiamine tetrahydrofurfuryl disulfide) is essentially the same as fursultiamine, popularized in the English-speaking naturopathic community by Derrick Lonsdale. These derivatives all ultimately deliver thiamine as the active moiety; their distinguishing feature is enhanced membrane penetration and, for CNS-targeted indications, blood-brain barrier penetration that water-soluble thiamine lacks.

Benfotiamine's anti-glycation mechanism. A specific mechanistic claim for benfotiamine in diabetic complications is that increased transketolase activity diverts excess glycolytic intermediates (glyceraldehyde-3-phosphate, fructose-6-phosphate) away from the three major hyperglycemia-driven damage pathways — the hexosamine pathway, the protein kinase C pathway, and the advanced glycation endproducts (AGE) pathway — and into the pentose phosphate shunt. This "Brownlee pathway" mechanism explains why benfotiamine is specifically attractive for diabetic complications rather than generic thiamine repletion. Translation to clinical benefit has been modest but consistent across several small trials.

Drug-induced thiamine deficiency. Several drug classes deplete thiamine: chronic loop diuretics (furosemide, bumetanide) increase urinary thiamine loss; metformin's effect is controversial (some studies suggest marginal reduction in tissue thiamine; most suggest it is clinically irrelevant compared to B12 depletion); 5-fluorouracil and high-dose levodopa produce thiamine-dependent enzyme inhibition by metabolite competition; chronic alcohol causes a multi-mechanism depletion via impaired absorption, impaired phosphorylation, and increased utilization.

Thiamine (vitamin B1) is the original vitamin — the deficiency syndrome beriberi was the clinical problem that gave rise to the entire vitamin concept, and the compound isolated from rice polishings by Jansen and Donath in 1926 and synthesized by Robert Williams in 1936 was literally the first "vital amine" (Casimir Funk coined the term vitamine in 1912 after investigating the anti-beriberi factor). The pharmacology is deceptively simple: thiamine is a water-soluble cofactor vitamin that, after phosphorylation to thiamine pyrophosphate (TPP, also called thiamine diphosphate or TDP), serves as the indispensable coenzyme for a handful of decarboxylase reactions that sit at the central intersection of glucose metabolism and amino acid catabolism. Without adequate TPP, the brain and heart fail in predictable patterns within weeks, and the resulting clinical syndromes — beriberi, Wernicke encephalopathy, Korsakoff psychosis, Shoshin fulminant cardiac beriberi — are among the most dramatic and preventable neurological emergencies in medicine. The adult RDA is 1.2 mg/day for men, 1.1 mg/day for women, 1.4 mg/day in pregnancy, and 1.4 mg/day in lactation. There is no formally established tolerable upper intake level for thiamine because it is among the safest vitamins known — the body does not substantially accumulate it (plasma half-life ~1-12 hours, whole-body half-life ~10-20 days), and excess oral or intravenous thiamine is cleared in the urine without known toxicity at gram-per-day doses. This makes thiamine an unusual vitamin: a potentially life-saving emergency medicine with essentially no ceiling on dosing in acute deficiency states, and a routine dietary requirement at low-milligram amounts in health. Western populations are largely protected from frank beriberi by grain fortification since the 1940s, but thiamine deficiency remains common in specific clinical contexts: chronic alcohol use (impaired absorption, impaired hepatic storage, and increased urinary loss combine to produce the classic Wernicke-Korsakoff picture, 12230201), hyperemesis gravidarum (protracted vomiting combined with increased metabolic demand in pregnancy can produce Wernicke encephalopathy in non-alcoholic women, with the additional risk of fetal demise), bariatric surgery (Roux-en-Y and sleeve patients are at life-long risk because of altered anatomy and variable adherence to supplementation), chronic furosemide therapy in heart failure (loop diuretics cause measurable urinary thiamine wasting, mechanistic rationale for supplementation in HF patients despite equivocal large RCT evidence, 11790067), refeeding syndrome (rapid carbohydrate reintroduction in the malnourished sharply increases TPP demand for glycolysis, precipitating acute deficiency and classically cardiovascular collapse unless thiamine is given before or with refeeding), chronic hemodialysis, HIV and advanced malignancy, and total parenteral nutrition without adequate micronutrients. Two monogenic disorders of thiamine transport produce inborn errors of metabolism that respond to pharmacologic thiamine: thiamine-responsive megaloblastic anemia syndrome (TRMA) from SLC19A2 (THTR1) mutations, presenting in infancy with megaloblastic anemia, diabetes, and sensorineural deafness, treatable with 25-100 mg/day thiamine; and biotin-thiamine-responsive basal ganglia disease from SLC19A3 (THTR2) mutations, presenting with episodic encephalopathy and dystonia responsive to high-dose biotin (5-10 mg/kg/day) plus thiamine (10-40 mg/kg/day). The supplement and clinical uses of thiamine cluster in several domains. Emergency parenteral thiamine (typically 500 mg IV over 30 minutes, three times daily for 2-3 days, then 250 mg IM/IV daily for 5 days, then transition to oral 100 mg three times daily) is the standard of care for suspected or confirmed Wernicke encephalopathy and is a BEFORE-glucose intervention in the alcoholic or malnourished patient presenting with altered mental status — giving IV glucose to a thiamine-depleted patient can precipitate acute Wernicke's by mass-action-driving thiamine-dependent pyruvate dehydrogenase and α-ketoglutarate dehydrogenase reactions. Chronic oral thiamine at 100-300 mg/day is used for ongoing alcohol use disorder, bariatric post-op, hyperemesis gravidarum prophylaxis/treatment, and refeeding syndrome prophylaxis. Benfotiamine, a lipid-soluble S-acyl thiamine derivative developed in Japan, is preferred for diabetic peripheral neuropathy based on the BENDIP trial and related work showing improved transketolase activity and modest neuropathy symptom improvement at 300-600 mg/day. Sulbutiamine, a lipophilic disulfide dimer of thiamine with isobutyryl esters, is marketed in France as Arcalion for asthenia and is discussed as a separate nootropic compound in its own right — see the Sulbutiamine entry. High-dose thiamine for Parkinson disease was advocated by the Italian neurologist Antonio Costantini based on open-label case series reporting dramatic motor symptom improvement with intramuscular thiamine 100-200 mg twice weekly; subsequent controlled evaluations have been preliminary and not definitively replicated, and the approach remains unproven despite enthusiastic patient communities. High-dose thiamine for heart failure has been studied in small RCTs with mixed results — Schoenenberger 2012 showed LVEF improvement in HF patients on furosemide given thiamine 300 mg/day for 28 days, but larger confirmatory trials are lacking. Thiamine as metabolic resuscitation in sepsis (the Marik HAT protocol — hydrocortisone, ascorbic acid, thiamine) generated enormous enthusiasm after Marik's 2017 before-after study but was not confirmed by the VITAMINS randomized trial in 2020 or subsequent replication attempts, and the HAT protocol is no longer recommended as standard sepsis care. Food sources concentrate in pork (a few ounces of pork loin meets daily RDA), whole grains, legumes, nuts and seeds, yeast extract (Marmite/Vegemite are extraordinarily rich sources), trout and other fish, beef liver, and fortified breakfast cereals. Thiamine is destroyed by heat, alkaline conditions, sulfites (the reason processed meats and some wines can deplete thiamine), and raw fish (certain fish contain thiaminases that cleave the vitamin — cooked fish is safe). See also Sulbutiamine for the lipophilic nootropic derivative, Magnesium for the TPP-kinase and PDH activation context (PDH is Mg-dependent for activation), Folate, Vitamin B6, Vitamin B12 for the broader B-vitamin family, Alpha-Lipoic Acid for the parallel PDH/αKGDH cofactor role, Choline for the alternative cholinergic precursor pathway, CoQ10 for the mitochondrial bioenergetic stack. This overview is educational only and is not medical advice — suspected thiamine deficiency, particularly Wernicke encephalopathy, is a medical emergency requiring immediate parenteral thiamine, not oral supplementation.

IUPAC Name

Not yet available

CAS Number

Not yet available

Molecular Formula

Not yet available

Molecular Mass

Not yet available

Unlock Dosing Protocols

Free account gets you:

• View beginner, intermediate & advanced protocols
• See weight-based dosing calculations
• Access cycle length & frequency data

2,800+ researchers already in

Unlock Research Data

Free account gets you:

• Browse PubMed study summaries
• See clinical trial phases & results
• Access mechanism of action details

2,800+ researchers already in

Get Thiamine Price Drop Alerts

Set a target price and we'll notify you when any vendor drops below it.

Sign in to set alerts

Related Compounds

View All

Related Articles

All Posts

Data Completeness

50%